The TissueCypher™ Barrett’s Esophagus Assay is the first test to combine protein expression with tissue structure information to predict risk of progression to high grade dysplasia (HGD) and esophageal adenocarcinoma (EAC) in patients with Barrett’s Esophagus. The test is intended for patients with diagnoses at the early end of the Barrett’s spectrum (non-dysplastic (ND), indefinite for dysplasia (IND) or low grade dysplasia (LGD)) where there is an opportunity to: i) identify high-risk patients and to intervene early with treatments such as RFA and EMR to prevent progression in the future, and ii) identify low-risk patients in whom surveillance intervals can be extended to minimize unnecessary use of care.